Literature DB >> 11141403

[Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin].

J M Baena Díez1, C López Mompó, F Rams Rams, M García Lareo, M Rosario Hernández Ibáñez, J Teruel Gila.   

Abstract

BACKGROUND: To evaluate the efficacy of a multistep strategy for Helicobacter pylori (HP) eradication. PATIENTS AND
METHOD: 151 patients, with peptic ulcer or chronic gastritis, infected by HP, treated (first-step) with omeprazole (20 mg/12 h), clarithromycin (500 mg/12 h) and amoxycillin (1 g/12 h) for a week (OCA) and second-step (first-step failures) with omeprazole (20 mg/12 h), metronidazole (500 mg/12 h), tetracyclin (500 mg/6 h) and bismuth (120 mg/6 h) for two weeks.
RESULTS: Intention-to-treat analysis, eradication was achieved with OCA in 78.1% (CI 95%: 71.6-84.7) and OMTB in 90.3% (CI 95%: 74.2-98), with an cumulative eradication rate of 96.7% (CI 95%: 92.4-98.9).
CONCLUSIONS: The efficacy of multistep strategy is high. Therapy with OMTB its a good option after failure with OCA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11141403     DOI: 10.1016/s0025-7753(00)71640-x

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  9 in total

1.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

Review 2.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

3.  Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.

Authors:  J P Gisbert; A Perez-Aisa; L Rodrigo; J Molina-Infante; I Modolell; F Bermejo; M Castro-Fernández; R Antón; B Sacristán; A Cosme; J Barrio; Y Harb; M Gonzalez-Barcenas; M Fernandez-Bermejo; A Algaba; A C Marín; A G McNicholl
Journal:  Dig Dis Sci       Date:  2013-10-15       Impact factor: 3.199

4.  Treatment of Helicobacter pylori Eradication Failures.

Authors:  Javier P. Gisbert; José María Pajares
Journal:  Curr Treat Options Gastroenterol       Date:  2003-04

5.  Trends in the eradication rates of Helicobacter pylori infection for eleven years.

Authors:  Jai Hoon Yoon; Gwang Ho Baik; Kyoung Min Sohn; Dae Yong Kim; Yeon Soo Kim; Ki Tae Suk; Jin Bong Kim; Dong Joon Kim; Jin Bae Kim; Woon Geon Shin; Hak Yang Kim; Il Hyun Baik; Hyun Joo Jang
Journal:  World J Gastroenterol       Date:  2012-12-07       Impact factor: 5.742

6.  High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin.

Authors:  Maribel Rodríguez-Torres; Rosa Salgado-Mercado; Carlos F Ríos-Bedoya; Edgardo Aponte-Rivera; Acisclo M Marxuach-Cuétara; José F Rodríguez-Orengo; Alberto Fernández-Carbia
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

7.  Rescue Therapy for Helicobacter pylori Infection 2012.

Authors:  Javier P Gisbert
Journal:  Gastroenterol Res Pract       Date:  2012-02-28       Impact factor: 2.260

8.  Comparison of the Eradication Rate between 1- and 2-Week Bismuth-Containing Quadruple Rescue Therapies for Helicobacter pylori Eradication.

Authors:  Jai Hoon Yoon; Gwang Ho Baik; Yeon Soo Kim; Ki Tae Suk; Woon Geon Shin; Kyung Ho Kim; Kyoung Oh Kim; Cheol Hee Park; Il Hyun Baik; Hyun Joo Jang; Jin Bong Kim; Sea Hyub Kae; Dong Joon Kim; Hak Yang Kim
Journal:  Gut Liver       Date:  2012-10-18       Impact factor: 4.519

9.  Eradication Rate of Helicobacter pylori using a Two-week Quadruple Therapy: A Report from Southern Iran.

Authors:  Mohsen Masoodi; Mohammad Panahian; Amirmansoor Rezadoost; Amin Heidari
Journal:  Middle East J Dig Dis       Date:  2013-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.